Clinical Trials

Lymphoma, Recurrence

NCT06875063 2026-03-13

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT07465835 2026-03-12

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

84 enrolled

Lymphoma

NCT03633955 2026-03-05

REALIZE

LymphoidOther hematologic neoplasmPlasma cell

60 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT06624085 2026-03-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

50 enrolled

Lymphoma

NCT01555892 2026-03-02

GRALE

136 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

15 enrolled

Lymphoma

NCT05892718 2026-02-04

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

80 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT05371132 2026-01-28

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

10 enrolled

Lymphoma, Neoplasm Metastasis

NCT06326463 2026-01-23

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

18 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03829540 2026-01-22

CD4CAR for CD4+ Leukemia and Lymphoma

20 enrolled

Leukemia, Lymphoma, Leukemia, T-Cell, Lymphoma, T-Cell

NCT04223765 2026-01-20

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

20 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06528301 2026-01-12

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

106 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06934382 2025-12-26

24CT015

33 enrolled

Lymphoma, Leukemia, T-Cell, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06022029 2025-12-24

ON-5001

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

168 enrolled

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT06441331 2025-12-17

KinLET

CNSEndocrineGastrointestinalLymphoidNETSarcoma

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT07280494 2025-12-12

S101MRD

18 enrolled

Lymphoma, Neoplasm, Residual

NCT05773040 2025-11-10

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

33 enrolled

Lymphoma, Lymphoma, B-Cell

NCT06420089 2025-11-10

VIPER101

30 enrolled

Lymphoma, Lymphoma, T-Cell

NCT06916767 2025-11-10

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

18 enrolled

Lymphoma

NCT04084067 2025-11-04

Indocyanine Green (ICG) Guided Tumor Resection

CNSGastrointestinalGenitourinaryLymphoidSarcoma

230 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lymphoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT06801002 2025-10-14

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

25 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT06733441 2025-10-10

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

50 enrolled

DermatologicLymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05365659 2025-10-01

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

140 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

46 enrolled

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04162353 2025-09-16

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05357651 2025-09-11

A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

100 enrolled

Lymphoma

NCT05983965 2025-09-10

Study of Tazemetostat in Lymphoid Malignancies

30 enrolled

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT07109518 2025-09-03

uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Lymphoma, Leukemia, Myeloid, Acute

NCT06340737 2025-08-07

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

148 enrolled

Burkitt Lymphoma, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07108868 2025-08-07

A Phase I Dose Finding Study of MB-CART2219.1

36 enrolled

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07106749 2025-08-06

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies

Burkitt Lymphoma, Lymphoma, Leukemia, Myeloid, Acute

NCT02917083 2025-07-25

RELY-30

60 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT05660395 2025-07-16

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

56 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

19 enrolled

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04827810 2025-06-29

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

42 enrolled

Lymphoma

NCT04637763 2025-03-24

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

72 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06132503 2025-03-17

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

110 enrolled

LymphoidSarcoma

Lymphoma, Neoplasms, Recurrence, Sarcoma

NCT04830137 2025-03-13

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

248 enrolled

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05607498 2025-03-03

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

150 enrolled

Lymphoma, Recurrence

NCT05341557 2025-01-27

A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

110 enrolled

Lymphoma

NCT06332430 2024-12-19

Intratumoral CAN2109 in Subjects With Solid Tumors

27 enrolled

Lymphoma

NCT05156203 2024-11-12

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

30 enrolled

Lymphoma

NCT06615193 2024-09-26

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

111 enrolled

Lymphoma, Hematologic Neoplasms

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

DermatologicLymphoidThoracic

499 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

10 enrolled

Lymphoma, Neoplasm Metastasis, Recurrence

NCT05528887 2022-09-06

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies